AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02560909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLUAD® influenza vaccine
Description: MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
Study NCT02560909 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUVIRAL®
Description: Standard 2015-2016 nonadjuvanted vaccine
Study NCT05075902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
Study NCT02002091 — intervention group
Intervention type: OTHER
Intervention: no specific treatment
Description: lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
Study NCT01728753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
Study NCT01728753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1800 mg BID on Day 1, then 800mg BID for Days 2 5
Study NCT01855048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-Rephasin® SAL200
Description: continuous intravenous infusion over 60 minutes
Study NCT01855048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INT200-Placebo
Description: Formulation buffer for continuous intravenous infusion over 60 minutes
Study NCT00775788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting to Breasts
Description: Fat injection of Fat to breasts
Study NCT01464463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT - active
Description: Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
Study NCT01464463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT - euthymic
Description: Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
Study NCT01464463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBASP
Description: Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship.
Study NCT02317536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure Product 1
Study NCT02317536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnipure Product 2
Study NCT02317536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01756066 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different levels of cost sharing
Study NCT03331380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scans - obj 3
Description: For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
Study NCT03331380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scans - obj 4
Description: For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
Study NCT01612416 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RS-3000 OCT measurements
Description: Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
Study NCT01612416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-3000 OCT measurements
Description: Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
Study NCT01751542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness + Residential Treatment
Study NCT01751542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential treatment alone
Study NCT01207999 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of cervical cancer tissue samples
Description: Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
Study NCT01207999 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion
Study NCT02260544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
Study NCT02260544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
Study NCT04158752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Injection of study drug at 3 timepoints (day 30, day 60, day 90)
Study NCT05993715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Description: Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
Study NCT05993715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementtaion
Description: 2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
Study NCT03953820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
Study NCT03953820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Description: Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
Study NCT03700593 — intervention group
Intervention type: DEVICE
Intervention: Single Port Robotic Colorectal Surgery
Description: Single Port Robotic Colorectal Surgery
Study NCT00448448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
Study NCT00448448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Clinical, radiographic, and self-report follow-up every 6 months.
Study NCT03501628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
Study NCT03501628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine + maltodextrin
Description: Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
Study NCT03501628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Description: Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
Study NCT03501628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein concentrate
Description: Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
Study NCT03501628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein concentrate
Description: Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02412670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Administered subcutaneously
Study NCT02412670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy
Description: Undergo nephroureterectomy and lymph node dissection
Study NCT01425476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study NCT01756066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Different levels of cost sharing
Study NCT00983840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Eats
Description: 8-session web-based program on healthy eating for African American families
Study NCT00983840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Eats
Description: 8-session web-based program on healthy eating for African American families
Study NCT03441893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: parasitological diagnostics (coproscopy)
Description: Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Study NCT03441893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: parasitological diagnostics (coproscopy)
Description: Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Study NCT03441893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide 500Mg Oral Tablet
Description: Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
Study NCT03441893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet
Description: Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
Study NCT03441893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 250Mg
Description: Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
Study NCT03441893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tabletes
Description: Tab. Placebo (shugar pills) will be given to the participants
Study NCT00839878 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study NCT00718289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrate dialysate
Description: dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
Study NCT00718289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetate dialysate
Description: dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
Study NCT02842112 — intervention group
Intervention type: OTHER
Intervention: PBSC mobilization and leukapheresis
Description: Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques.
Study NCT02771652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-training
Description: The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
Study NCT02771652 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
Study NCT03385382 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone intravitreal implant 0.7 mg
Description: Intravitreal Implant of dexamethasone
Study NCT03385382 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab Injection
Description: Injection of ranibizumab
Study NCT04494555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static socket
Description: For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
Study NCT04494555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: User adjusted socket
Description: Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
Study NCT04494555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprocessor-adjusting sockets
Description: A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation.
Study NCT04684914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepTcell
Description: Intramuscular injection
Study NCT04684914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT03286712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renogen
Description: Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
Study NCT00985556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00985556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00985556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-gimeracil-oteracil potassium
Description: Given orally
Study NCT02028585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat milk group
Study NCT02411383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx Diaphragm Pacing System
Description: NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
Study NCT04348656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
Study NCT01532713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oxygen administration
Description: nasal O2 5L/min via nasal cannula
Study NCT03056976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture
Description: Complete mandibular denture retained by a single midline implant
Study NCT01047579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivastigmine transdermal
Study NCT02560974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
Study NCT02560974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.